Zyflamend Herbal Product Has Anti-Inflammatory and Other Potential
Author: Thomas C. Weiss
Published: 2013/03/23 - Updated: 2021/05/10
Topic: Herbalism and Herbs - Publications List
Page Content: Synopsis - Introduction - Main
Synopsis: Zyflamend is a combination of herbal extracts including a full-spectrum blend of 10 remarkable herbs and dual extracts of Turmeric. Zyflamend contains herbs with anti oral cancer potential. A study done on rodents in the year 2008 demonstrated potential benefits of this supplement against oral cancer.
Introduction
Zyflamed is an herbal product used for its anti-inflammatory potential and other possible benefits. It is a combination of a number of herbal extracts and unlike other herbal products that are available on the market today, the creators of Zyflamend have actually gone through the trouble of conducting tests on their product. The tests they have performed are not easily conducted due to the need for time and planning, as well as the costs associated with the testing.
Main Item
Some of the early research has presented results that are promising, yet until a number of long-term human studies are performed, it will not be known what kind of effect a Zyflamend supplement will have on human disease and health.
In vitro studies have revealed that Zyflamend suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct through a process referred to as, 'apoptosis.' It has the ability, in culture at least, to reduct the growth of prostate cancer cells. The question remains - will the same benefit happen in people when it is taken as a supplement? The answer is simply unknown.
Zyflamend's Anti-Inflammatory Potential
The herbal blend in Zyflamend does have some anti-inflammatory potential. The product contains herbs including:
The product has a number of, 'phytonutrient,' ingredients as well. The polyherbal preparation is designed based upon constituents that exhibit anti-inflammatory, anti-proliferative, antioxidant, apoptotic, and anti-angiogenic activities through mechanisms that have yet to be well defined.
- Rosemary: Rosemary herb is becoming increasingly popular.
- Ginger: Ginger extract offers people a number of beneficial constituents.
- Green Tea: Green tea has potent, 'polyphenols,' and has been highly praised by both scientists and the media.
- Oregano: Oregano is a source of a large number of compounds that promote a healthy inflammatory response.
- Scutellaria: Scutellaria or, 'Scullcap,' is a unique, 'baicalin phytonutrient,' complex. It naturally supports a healthy inflammatory response.
- Turmeric: Turmeric is a unique, 'curcumin phytonutrient,' complex that might present added benefit when it is combined with green tea polyphenols.
- Basil: Basil or, 'Ocimum sanctum,' contains ursolic acid - something that might enhance detoxification while supporting the inflammation response.
- Barberry: Barberry or, 'Chinese Goldthread,' has a unique, 'beberine phytonutrient,' complex and naturally supports a person's inflammation response system.
- Hu Zhang: Hu Zhang or, 'Polygonum caspidatum,' is an herb that presents one one of the richest known content of resveratrol. Resveratrol is a compound that has been found in rodents to contain potential anti-aging properties.
Studies in Animals and Benefits for Oral Cancer
Zyflamend contains herbs with anti oral cancer potential. A study done on rodents in the year 2008 demonstrated potential benefits of this supplement against oral cancer. Zyflamend reduces LTB4 formation and prevents oral cacinogenesis in a 7,12 dimethylbenz [alpha] antracene (DMBA)-induced hamster cheek pouch model. The study was performed at the University of Texas Anderson Cancer Center in Houston at the Department of Experimental Therapeutics. According to the study performed;
"Aberrant arachidonic acid metabolism, especially altered cyclooxygenase and 5-lipoxygenase (LOX) activities, has been associated with chronic inflammation as well as carcinogenesis in human oral cavity tissues. Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma."
The study suggested that the herbal combination may prevent oral cacinogenesis at the post-initiation stage.
Zyflamend and Prostate Cancer
Zyflamend's influence on prostate cancer in humans is not fully known at this time. The reason for this is because to find out for certain, Zyflamend would need to be administered for at least a decade in a population of older men and then compared to another group that had been administered a placebo. Since there has been no study of this type performed, no one knows for certain - yet the early results appear promising.
A Phase I study, performed through the Department of Urology at Columbia University's College of Physicians and Surgeons in New York, found that people diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) at biopsy are at an increased risk for developing prostate cancer (CaP). A prospective trial was done to determine the tolerability and safety of Zyflamend, considered to be a novel herbal amalgam, with different dietary supplements in people with HGPIN. Men between the ages of 40 and 75 with HGPIN were eligible to participate and were evaluated for a period of 18 months.
Every 3 months, standard blood chemistries and prostate-specific antigen (PSA) were monitored during the study. Re-biopsy was performed every 6 months. The men's tissues were evaluated for HGPIN or prostate cancer and stained for, 'cyclooxygenase-2,' nuclear factor kappaB (NF-kappaB), as well as thomboxane and interleukin-6.
The mean PSA leveal was 6 ng/mL. The side effects the men experienced, when they experienced any at all, were mild and involved gastrointestinal upset. There were no reported serious adverse events or toxicities on the part of the participants. No significant changes in their blood chemistries, cardiac function, or testosterone were noted. Just short of half of the men, 48%, demonstrated a 25-50% decrease in PSA after a period of 18 months.
Out of the participants who had the 18-month biopsy, 60% had benign tissue, 26% had HGPIN in one core, while 13% had CaP at 18 months. A reduction in their serum C-reactive protein was observed. Their immuno-reactive staining revealed a reduction in NF-kappaB in the samples taken at 18 months. Zyflamend alone and in combination with different dietary supplements associated with minimal toxicity. The men experienced no serious adverse effects when it was administered orally over a period of 18 months.
Author Credentials: Thomas C. Weiss is a researcher and editor for Disabled World. Thomas attended college and university courses earning a Masters, Bachelors and two Associate degrees, as well as pursing Disability Studies. As a CNA Thomas has providing care for people with all forms of disabilities. Explore Thomas' complete biography for comprehensive insights into his background, expertise, and accomplishments.